BRAINSTORM CELL THERAPUTC
BCLI
BCLI was delisted on the 17th of July, 2025.
32 hedge funds and large institutions have $1.09M invested in BRAINSTORM CELL THERAPUTC in 2025 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 7 increasing their positions, 3 reducing their positions, and 6 closing their positions.
133% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 3
95% more capital invested
Capital invested by funds: $560K → $1.09M (+$531K)
10.86% more ownership
Funds ownership: 7.09% → 17.95% (+11%)
6% less funds holding
Funds holding: 34 → 32 (-2)
33% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$1.22M |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$10K |
| 3 |
TSS
Two Sigma Securities
New York
|
+$8.59K |
| 4 |
BSB
Bangor Savings Bank
Bangor,
Maine
|
+$471 |
| 5 |
Jones Financial Companies
Des Peres,
Missouri
|
+$382 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$89.8K |
| 2 |
HF
HRT Financial
New York
|
-$45K |
| 3 |
IC
Ikarian Capital
Dallas,
Texas
|
-$13.7K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$5.7K |
| 5 |
Citigroup
New York
|
-$4.47K |
BCLI Hedge Fund Activity: Q1 2025 in Review
32 of the 7,457 institutional investors tracked by Wall St. Rank reported a position in BRAINSTORM CELL THERAPUTC (BCLI) for Q1 2025, worth a combined $1.09M — up 95% from $560K a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of BCLI and 4 opened new positions — a net loss of 2 holders — while 3 trimmed existing stakes and 7 added.
The largest buyer was Armistice Capital, opening a new position worth an estimated $1.22M. The largest seller was Vanguard Group, cutting an estimated $89.8K.
- 32 institutional investors held BRAINSTORM CELL THERAPUTC (BCLI) as of Q1 2025, down from 34 in Q4 2024.
- Funds reported $1.09M of BRAINSTORM CELL THERAPUTC stock for Q1 2025, up 95% quarter-over-quarter.
- 4 funds opened new BRAINSTORM CELL THERAPUTC positions in Q1 2025 and 6 closed out, a net change of -2 holders.
- The largest BRAINSTORM CELL THERAPUTC buyer in Q1 2025 was Armistice Capital, an estimated $1.22M added.
- The largest BRAINSTORM CELL THERAPUTC seller in Q1 2025 was Vanguard Group, an estimated $89.8K sold.
Based on aggregated 13F filings for Q1 2025.